Topical macrolide immunomodulators: a role in the treatment of vitiligo?
Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases, such as psoriasis, lichen planus, and even vitiligo, is expanding rapidly. It is generally accepted that autoimmune factors play an important role in vitiligo. In this article, the possible use and mechanism of topical macrolide immunomodulators in the treatment of vitiligo are discussed, together with the current state of clinical studies and case reports. These limited reports indicate that topical macrolide immunomodulators may play a role in the treatment of vitiligo, particularly in areas where use of potent corticosteroids is contraindicated.
Tjioe
Milan
M
Department of Dermatology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands. M.Tjioe@derma.umcn.nl
Vissers
Wynand H P M
WH
Gerritsen
Marie-Jeanne P
MJ
D000279:Administration, Cutaneous; D065095:Calcineurin Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D018942:Macrolides / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D014820:Vitiligo / Q000188:drug therapy* / Q000473:pathology
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D018942:Macrolides; C117268:pimecrolimus; D016559:Tacrolimus